SCHEMBL1676145

SCHEMBL1676145

COc1ccc(-c2nc(-c3ccc(Cl)cc3Cl)cn2Cc2ccc(-c3cccc(C(F)(F)F)c3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 2/20 0.47
GRIN1 Q05586 1/20 0.47
GPR55 Q9Y2T6 1/20 0.44
BACE1 P56817 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KDR P35968 1/20 0.42
TEK Q02763 1/20 0.42
NR1H4 Q96RI1 1/20 0.41
CXCR2 P25025 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
DPP4 P27487 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676632 0.88 PTGS1 (0.45) GRIN2BGRIN1KDRTEKKDM4E
SCHEMBL1676439 0.88 GPR34 (0.41) GRIN2BGRIN1NPC1RAB9AKDR
SCHEMBL1676444 0.88 DRD2 (0.43) NPC1RAB9ASMN1; SMN2DPP4MAPT
SCHEMBL1676381 0.87 PPARD (0.43) GRIN2BMAPT
SCHEMBL1676231 0.85 KDM4E (0.46) GRIN2BNPC1RAB9AKDM4EALDH1A1
SCHEMBL1676460 0.85 FFAR4 (0.41) KDR
SCHEMBL1676515 0.82 NPC1 (0.48) NPC1RAB9ACXCR2ALDH1A1DPP4
SCHEMBL1676020 0.79 NPC1 (0.56) NPC1RAB9ACXCR2KDM4EALDH1A1
SCHEMBL1676238 0.79 S1PR5 (0.38) GRIN2BKDRTEKALDH1A1SMN1; SMN2
SCHEMBL1676348 0.78 NPC1 (0.55) NPC1RAB9ACXCR2DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE GRIN2B 4662/4885GRIN1 4191/4885GPR55 2846/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE GRIN2B 4662/4885GRIN1 4191/4885GPR55 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.